High Let-7a MicroRNA Levels in KRAS-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease Full Text
The Oncologist, 06/22/2012
Ruzzo A et al. – In patients with KRAS mutations, Lethal–7 (Let–7)a analysis may serve to identify subgroups of patients who may still benefit from epidermal growth factor receptor (EGFR) inhibition and this may open up new perspectives for alternative treatment strategies.



